Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Tolvaptan

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

4Total
Phase 2 (1)
Phase 3 (3)

Trial Status

Completed4

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT06949020Phase 2CompletedPrimary

A Dose-finding Study of JMKX003142 in Treatment of Cardiac Edema

NCT00544869Phase 3CompletedPrimary

A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)

NCT01651156Phase 3CompletedPrimary

Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema

NCT00525265Phase 3CompletedPrimary

A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Showing all 4 trials

Research Network

Common Treatments

  • Tolvaptan1
  • Opc41061tolvaptan1
  • Jmkx003142 Injection1
  • Opc41061 Tolvaptan1

Active Sponsors

  • Otsuka Pharmaceutical Co., Ltd.2
  • Jemincare1
  • Otsuka Beijing Research Institute1

Top Investigators

Activity Timeline